Repair Inducing Cognition Enhancers (RICE)

"Science for patients"

Prof. dr. Tim Vanmierlo

Cognition
Remyelination
Phosphodiesterase
Multiple Sclerosis
Alzheimer's disease


Contact:
+32 (11) 26 92 28
tim.vanmierlo@uhasselt.be

Research focus

Therapeutic research in neurodegeneration mainly focusses on molecular mechanisms and disease hallmarks, but improvement on the functional level is often neglected. Therefore, the “repair team” of the NIC&R group couples a cognitive readout to molecular interventions in treatment of CNS damage so that we can provide a translational interpretation towards first-in-man trials. We focus on neurodegenerative disorders such as multiple sclerosis and Alzheimer’s disease.

You can contact us for:

  • Functional and molecular readouts in animal models of multiple sclerosis and Alzheimer’s disease
  • Molecular and cellular setups in relation to oligodendrocyte differentiation
  • In vitro and in vivo gene-editing tools to modulate (epi)genetic processes on the cellular level (e.g. CRISPR/Cas9, in vivo micro-electroporation)

Short Bio

This research is integrated within the NIC&R group and is related to the research of Niels Hellings and Bieke Broux.

Publications

Peer reviewed pubmed (ncbi) publications: 82

Hirsch index Web of Science: H=27 (Sum of citations: 2048)

Hirsch index Google scholar : H=31 (Sum of citations: 2909)

  1. Koulousakis P. *, Tiane A*. Hellings N., Prickaerts J. van den Hove D. *, Vanmierlo T. * A perspective on causality assessment in epigenetic research on neurodegenerative disorders. Neural Regeneration Research 2023 (in press) (IF 6.06)
  1. Tiane A., Schepers M., Riemens R., Rombaut B., Vandormael P., Somers V., Prickaerts J., Hellings N., van den Hove D. *, Vanmierlo T.* DNA methylation regulates the expression of the negative transcriptional regulators ID2 and ID4 during OPC differentiation. Cell Mol Life Sci. 2021 Oct;78(19-20):6631-6644. (IF 9.18)
  1. Rombaut B., Kessels S., Schepers M., Tiane A., Paes D., Solomina Y., Piccart E., van den Hove D., Brône B., Prickaerts J. and Vanmierlo T. PDE inhibition in distinct cell types to reclaim the balance of synaptic plasticity. Theranostics. 2021 Jan 1;11(5):2080-2097. (IF 11.60)
  1. van Veggel L.*, Spaas J.*, Schepers M., Tiane A., van Horssen J., Wilson D.M.III, Moya P., Piccart E., Hellings , Eijnde B.O., Derave W., Schreiber R., Vanmierlo T. Oxidative stress and impaired oligodendrocyte precursor cell differentiation in neurological disorders. Cell Mol Life Sci. 2021 May;78(10):4615-4637 (IF 9.18)
  1. Martens N.*, Schepers M.*, Zhan N., Leijten F., Voortman G., Tiane A., Rombaut B., Poisquet J., van de Sande N., Kerksiek A., Kuipers F., Jonker J., Liu H. , Lütjohann D. *, Mulder T. *,
    Vanmierlo T. * 24(S)-Saringosterol prevents cognitive decline in a mouse model for Alzheimer’s disease. Mar Drugs. 2021 Mar 27;19(4):190. (IF 6.09)

Patent applications

  • 10/10/2019 publication PCT Patent Application with Application numbers EP18165843.6 PCT/EP2019/05495 WO 2019/193091 on “Selective PDE4D inhibitors against demyelinating diseases”
  • 02/06/2021 “COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR USE IN NEURODEGENERATIVE DISORDERS” - EP21177320.5

Team

Core Techniques

  • Oligodendrocyte differentiation
  • Epigenetic editing (CRISPR-dCas)
  • Pyrosequencing
  • Functional and molecular readouts in animal models of multiple sclerosis and Alzheimer’s disease
  • Molecular and cellular setups in relation to microglial functioning
  • In vitro and in vivo gene-editing tools to modulate (epi)genetic processes on the cellular level
  • (e.g. CRISPR/Cas9, in vivo micro-electroporation)
  • In silico: Exon composition mapping and isoform expression profiling (using ExonArray data or qPCR).
  • In vitro:Isoform-specific knockdown and characterization of neuronal differentiation.
  • In vivo: Cognitive phenotyping of rodents in behavioural tests.

Media